- $15.57bn
- $14.73bn
- $2.32bn
Brief: Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors
Brief: FDA Approves Cabozantinib For Adults And Pediatric Patients 12 Years Of Age And Older With pNET And epNET
Brief: Exelixis Announces A Newly Authorized $500 Million Stock Repurchase Program
Exelixis Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Exelixis Q4 Revenue USD 567 Million Vs. IBES Estimate USD 563.4 Million
U.S. RESEARCH ROUNDUP- Fair Isaac, Mastercard, McKesson
U.S. RESEARCH ROUNDUP- Constellation Brands, Merck, WD-40
Brief: Exelixis Inc Says FY 2025 Net Product Revenues Guidance $1.95 Billion - $2.05 Billion
U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent
Brookline Capital Markets initiates Exelixis with 'buy' rating
Unsupported price hikes added $815 mln to US drug spending in 2023 (updated)
Unsupported price hikes added $815 mln to US drug spending in 2023
Brief: Exelixis Provides Regulatory Update Related To Supplemental New Drug Application For Cabozantinib
Exelixis Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Exelixis Q3 Revenue USD 539.5 Million Vs. IBES Estimate USD 490 Million
U.S. STOCKS ON THE MOVE-Wave Life Sciences, Dominion Energy, Voyager Therapeutics
U.S. STOCKS ON THE MOVE-United Airlines, Morgan Stanley, Autodesk
Brokerages raise PT on Exelixis after favorable court ruling in patent dispute case
U.S. RESEARCH ROUNDUP-Autozone, State Street, UnitedHealth